AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), Ocugen Inc (NASDAQ: OCGN), and Tarena International Inc (NASDAQ: TEDU) are headed for not so good days ahead with their investors. Bragar Eagel & Squire, P.C., a shareholder rights law firm known across the nation, informs investors that class actions are initiated on behalf of stockholders of the three companies. Further, the law firm informed that stockholders of the three companies must submit a petition in the court before the individual deadline for the respective companies. Individual and institutional investors in commercial, securities, derivatives are clients of the law firm.
FDA warned AcelRx Pharmaceuticals Inc for misleading promotion of DSUVIA drug
AcelRx Pharmaceuticals Inc made an official statement that the Food and Drug Administration (FDA) in the U.S. has given the company the go-ahead for DSUVIA. The drug is used in emergency departments, hospitals, and healthcare centers for pain management in adults. However, it came to light that the FDA sent a warning letter to AcelRx Pharmaceuticals Inc to provide false information and for indulging in the misleading promotion of DSUVIA drug. As soon as the news broke, the stock of the company fell. The lead plaintiff deadline is August 9, 2021.
Ocugen, Inc alleged for not disclosing certain important information
Meanwhile, Ocugen Inc, in a statement, announced that it would file an Emergency Use Authorization (EUA) with the FDA for COVAXIN, a COVID-19 vaccine, in June. However, in the same month, the company made it official to go ahead with work towards submitting an application seeking full U.S. approval of the shot. Throughout the Class Period, Ocugen Inc is accused of making false and misleading statements and being accused of disclosing certain information.
Tarena International Inc is accused of making misleading and false statements
In another development, it is learned that Tarena International Inc is held responsible for providing false and misleading statements related to its operations and business. In addition, it is alleged that the company submitted incorrect financial statements from 2014 through the end of the Class Period. When news of the wrongdoing of Tarena International Inc broke, its share price plunged.